SGLT2 inhibitors combined with GLP-1 receptor agonists reduce serious renal events compared to GLP-1 receptor agonist monotherapy
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.